Danaher Corporation (DHR - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 15.8% in the past one-month time frame.
The move came after the company announced that it has inked a definitive agreement with General Electric to acquire the latter’s biopharmaceutical business for roughly $21.4 billion.
The company’s Zacks Consensus Estimate for the current quarter has moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Danaher currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Danaher Corporation Price
Investors interested in the Diversified Operations industry may consider Griffon Corporation (GFF - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is DHR going up? Or down? Predict to see what others think:Up or Down
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>